<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5227">
  <stage>Registered</stage>
  <submitdate>30/10/2015</submitdate>
  <approvaldate>30/10/2015</approvaldate>
  <nctid>NCT02596477</nctid>
  <trial_identification>
    <studytitle>Evaluation of Vepoloxamer in Chronic Heart Failure</studytitle>
    <scientifictitle>A Phase 2 Randomized, Double-Blind, Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vepoloxamer Injection, 22.5% (Sodium-Free) in Ambulatory Subjects With Chronic Heart Failure</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>MST-188-09</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Heart Failure</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Vepoloxamer
Other interventions - 5% dextrose in water

Experimental: Vepoloxamer - Low dose - Vepoloxamer injection administered intravenously 225 mg/kg over 3 hours

Experimental: Vepoloxamer - High dose - Vepoloxamer injection administered intravenously 450 mg/kg over 3 hours

Placebo Comparator: 5% dextrose in water (D5W) - D5W administered intravenously over 3 hours


Treatment: drugs: Vepoloxamer


Other interventions: 5% dextrose in water


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of subjects with a change in cardiac biomarkers ultra-high sensitive troponin I and NT-proBNP</outcome>
      <timepoint>Study Day 1 through Study Day 30</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of subjects with a change in Six Minute Walk test</outcome>
      <timepoint>Study Day 1 to Study Day 30</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of subjects with a change in Borg dyspnea index</outcome>
      <timepoint>Study Day 1 to Study Day 30</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of subjects with a change in Minnesota Living with Heart Failure QuestionnaireÂ®</outcome>
      <timepoint>Study Day 1 to Study Day 30</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of subjects with a change in left ventricular end diastolic volume index</outcome>
      <timepoint>Study Day 1 to Study Day 30</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of subjects with treatment-related adverse events as assessed by CTCAE v 4.03</outcome>
      <timepoint>Study Day 1 to Study Day 30</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age 18 through 74

          -  Duration of documented heart failure &gt;3 months

          -  On stable concomitant medication regimen =4 weeks

          -  Left ventricular ejection fraction =35%

          -  Systolic blood pressure =90 mmHg</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Severe valvular stenosis or primary valvular regurgitation as the cause of heart
             failure

          -  History of myocardial infarction, coronary artery bypass graft surgery, or
             percutaneous intervention within the prior 3 months

          -  Estimated glomerular filtration rate =45 mL/min/1.73 m2

          -  Acutely decompensated heart failure within 1 month prior to the screening visit</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>10</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Research Center - Cardiff</hospital>
    <hospital>Research Center - Melbourne</hospital>
    <postcode>2285 - Cardiff</postcode>
    <postcode> - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Mast Therapeutics, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate whether vepoloxamer can provide a blood chemical
      marker and functional benefit to damaged heart muscle cells. This will be evaluated by
      measurement of blood-based laboratory markers, exercise tolerance, and echocardiograms. In
      addition, the safety and blood levels of vepoloxamer in subjects with chronic heart failure
      will be evaluated.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02596477</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Edwin L. Parsley, D.O.</name>
      <address>Mast Therapeutics, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>